News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Driven by the Launch and Uptake of Genome BioSciences Inc./GlaxoSmithKline (GSK)'s Benlysta, the Systemic Lupus Erythematosus Drug Market Will Increase More Than Seven-Fold to $2.1 Billion in 2020


10/25/2011 9:39:51 AM

BURLINGTON, Mass.--(BUSINESS WIRE)--Decision Resources, one of the world’s leading research and advisory firms for pharmaceutical and healthcare issues, finds that, driven primarily by the launch and uptake of Human Genome Sciences/GlaxoSmithKline’s Benlysta, the systemic lupus erythematosus (SLE) drug market will increase more than seven-fold, from approximately $300 million in 2010 to more than $2.1 billion in 2020 in in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES